2024
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaDietary modificationSupplement useDiagnosis of renal cell carcinomaFirst-line treatmentSupplement usageSystemic therapyCombination therapyAntineoplastic therapyKetogenic dietCarcinomaCancer therapyMediterranean dietPhysician-patient dialoguePatientsTherapyCancer treatmentGrowing body of evidenceBody of evidenceDietary changesCancerCancer diagnosisCannabidiol
2023
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety ScaleEvaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
Feng M, Prajapati S, Castro D, Lee K, Chan E, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 34-34. DOI: 10.1200/jco.2023.41.6_suppl.34.Peer-Reviewed Original ResearchType of treatmentExclusion criteriaBrain metastasesEligibility criteriaExact testHBV/HCVMetastatic prostate cancerFisher's exact testChi-square testClinical eligibilityConcurrent malignancyHCV positivityHormone therapyHIV positivityCombination therapyRadioligand therapyClinical trialsProstate cancerProstate cancer studyRadiation therapyClinical OncologyTherapyCancer typesMeSH termsPhase IAssessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
Castro D, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Zengin Z, Li X, Chehrazi-Raffle A, Dizman N, Tripathi A, Rock A, Liu S, Mercier B, Meza L, Philip E, Dorff T, Pal S. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations. Journal Of Clinical Oncology 2023, 41: 453-453. DOI: 10.1200/jco.2023.41.6_suppl.453.Peer-Reviewed Original ResearchHIV positivityHCV positivityEligibility criteriaCancer trialsExclusion criteriaConcurrent malignancyBrain metastasesCombination therapyExact testClass of therapyTrial eligibility criteriaReal-world populationFisher's exact testRestrictive eligibility criteriaSpecific study populationMultiple cancer typesChemotherapy trialsReal-world practiceInvestigational treatmentStudy populationRadiation therapyClinical OncologyPrognostic toolTherapySignificant association
2022
Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
Govindarajan A, Castro D, Zengin Z, Salgia S, Patel J, Pal S. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers 2022, 14: 2049. PMID: 35565179, PMCID: PMC9106028, DOI: 10.3390/cancers14092049.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsRenal cell carcinomaCheckpoint inhibitorsCell carcinomaMetastatic renal cell carcinoma (mRCC) therapyFront-line settingFront-line therapyRenal cell carcinoma therapyDoublet therapyDurable responsesOverall survivalClinical outcomesCombination therapyTherapy optionsTreatment paradigmTreatment selectionDrug AdministrationCarcinoma therapyTherapyCarcinomaInhibitorsFuture directionsAdministrationVEGFR
2021
First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).
Dizman N, Hsu J, Gillece J, Folkerts M, Reining L, Bergerot P, Meza L, Zengin Z, Muddasani R, Chawla N, Karimi M, Trent J, Highlander S, Pal S. First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO). Journal Of Clinical Oncology 2021, 39: 337-337. DOI: 10.1200/jco.2021.39.6_suppl.337.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaClinical benefitClear cell histologyMajority of ptsRenal cell carcinomaMedian relative abundanceCell histologyMetastatic diseaseClinical outcomesCell carcinomaDiscriminant analysis effect sizePancreatic cancerLinear discriminant analysis effect sizeImmunotherapyLarge seriesSerial samplesPotential associationFungal elementsPatientsMalassezia sppMultiple timepointsMicrobiome compositionTherapyEffect sizeAspergillus fumigatus
2020
Tivozanib in renal cell carcinoma: a new approach to previously treated disease
Salgia N, Zengin Z, Pal S. Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances In Medical Oncology 2020, 12: 1758835920923818. PMID: 32547647, PMCID: PMC7249546, DOI: 10.1177/1758835920923818.Peer-Reviewed Original ResearchPhase III trialsIII trialsMulti-institutional phase III trialVascular endothelial growth factor receptor tyrosine kinasesEarly clinical trialsRenal cell carcinomaManagement of RCCVEGF-TKICell carcinomaClinical trialsTargeted therapyTreatment paradigmMultikinase inhibitorClinical dataFurther trialsGrowth factor receptor tyrosine kinaseTivozanibDisease settingsClinical toolReceptor tyrosine kinasesTrialsRCCTherapyTyrosine kinaseCarcinoma